Triamcinolone NEW
| Price | $45 |
| Package | 500mg |
| Supply Ability: | 10g |
| Update Time: | 2025-05-01 |
Product Details
| Product Name: Triamcinolone | CAS No.: 124-94-7 |
| Purity: 99.54% | Supply Ability: 10g |
| Release date: 2025/05/01 |
Product Introduction
Bioactivity
| Name | Triamcinolone |
| Description | Triamcinolone (Aristocort) is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. Upon cell entry, triamcinolone binds to and activates the glucocorticoid receptor, which leads to translocation of the ligand-receptor complex to the nucleus and induces expression of glucocorticoid-responsive genes such as lipocortins. Lipocortins inhibit phospholipase A2, thereby blocking the release of arachidonic acid from membrane phospholipids and preventing the synthesis of prostaglandins and leukotrienes, both mediators of inflammation. In addition, pro-inflammatory cytokine production, including interleukin (IL)-1and IL-6, and the activation of cytotoxic T-lymphocytes is also inhibited. T-cells are prevented from making IL-2 and proliferating. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis through increasing Ikappa-B expression and curtailing activation of nuclear factor (NF)kappa-B. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 1 mg/mL (2.54 mM), Sonication is recommended. DMSO : 55 mg/mL (139.44 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) |
| Keywords | Triamcinolone | Inhibitor | inhibit | GlucocorticoidReceptor | Glucocorticoid Receptor | COX | Bacterial |
| Inhibitors Related | Bismuth Subsalicylate | Ibuprofen | Acetaminophen | Salicylamide | Diclofenac sodium | Diclofenac Potassium | Dexamethasone | Paradol | Indomethacin sodium hydrate | Salicylic acid | Glafenine | Revaprazan hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Human Metabolite Library | Anti-Cancer Drug Library |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-08-05 | ||
| $45.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-07-27 | |
| $45.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-07-27 | |
|
Hebei Chuanghai Biotechnology Co., Ltd
|
2025-06-27 | |||
| $100.00 |
Hebei Yanxi Chemical Co., Ltd.
|
2025-06-20 | ||
|
VIP3Y
|
Shaanxi TNJONE Pharmaceutical Co., Ltd
|
2025-04-02 | ||
| $1.00 |
Guangzhou Biocar Biotechnology Co.,Ltd.
|
2022-12-29 | ||
| $200.00 |
Wuhan Qiami Technology Co., Ltd
|
2022-07-15 | ||
| $10.00 |
Wuhan Demeikai Biotechnology Co., Ltd
|
2021-12-14 | ||
| $15.00 |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-13 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY